Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease

Autor: Borchert RJ 1, Rittman T 1, Passamonti L 1, 2, Ye Z 3, Sami S 1, Jones SP 1, Nombela C 4, Vázquez Rodríguez P 1, Vatansever D 5, Rae CL 6, 7, Hughes LE 1, 8, Robbins TW 9, Rowe JB 1

Publikováno v: Neuropsychopharmacology (N.Y. N.Y.) (2016). doi:10.1038/npp.2016.18
info:cnr-pdr/source/autori:Borchert RJ 1, Rittman T 1, Passamonti L 1,2, Ye Z 3, Sami S 1, Jones SP 1, Nombela C 4, Vázquez Rodríguez P 1, Vatansever D 5, Rae CL 6,7, Hughes LE 1,8, Robbins TW 9, Rowe JB 1,8,9./titolo:Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease./doi:10.1038%2Fnpp.2016.18/rivista:Neuropsychopharmacology (N.Y. N.Y.)/anno:2016/pagina_da:/pagina_a:/intervallo_pagine:/volume

Cognitive impairment is common in Parkinson's disease (PD), but often not improved by dopaminergic treatment. New treatment strategies targeting other neurotransmitter deficits are therefore of growing interest. Imaging the brain at rest ('task-free'

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::103a013f52726f4891aad6ce977a1f65